Company Overview of F2G Ltd
F2G Ltd. discovers and develops novel drugs to treat life threatening fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company offers orotomides that are active against Aspergillus and other filamentous molds. F2G Ltd. was founded in 1998 and is based in Manchester, United Kingdom.
Manchester, M30 0LX
Founded in 1998
44 1617 851 270
44 1617 851 273
Key Executives for F2G Ltd
F2G Ltd Key Developments
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
June 20, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact F2G Ltd, please visit www.f2g.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.